Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
about
Diabetic macular edema: it is more than just VEGFUpdates on the Clinical Trials in Diabetic Macular EdemaNovel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Retinal microvascular alterations related to diabetes assessed by optical coherence tomography angiography: A cross-sectional analysis.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesA novel device for accurate and efficient testing for vision-threatening diabetic retinopathy.Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research NetworkAflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.Current and investigational drugs for the treatment of diabetic retinopathy.Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Evidence-Based Treatment of Diabetic Macular Edema.Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).Combination of Navigated Macular Laser Photocoagulation and Anti-VEGF Therapy: Precise Treatment for Macular Edema under Dry Retinal Conditions.Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review.Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications.Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society).Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema.Protective effects on the retina after ranibizumab treatment in an ischemia modelDexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome.Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema.Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study.Recent advances in the management and understanding of diabetic retinopathy.Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol.Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.Management of diabetic macular edema in Japan: a review and expert opinion.Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab.Aflibercept in the treatment of diabetic macular edema: a review and consensus paper.
P2860
Q26745914-CD6A5A06-AB9D-4744-A47A-B52D7B3D1363Q26767100-82ED2EEE-EE0E-42C3-8BC1-2287BDBA234DQ28066675-2ECC97AC-EC6E-426F-ACCB-CFEECB8240C6Q30101045-9369E3C5-2224-47A0-8D8C-1E0780D9D169Q33597198-9DEF0940-C623-4240-B95F-35503D6A80AFQ33840787-23D17705-DBA4-42A9-996B-EEFF10183001Q34510550-F085E912-E75A-4742-B362-17A07CEB7FF3Q35870506-B8711D5B-6598-4F72-99F9-991835DC27DDQ35935370-67EB8D3D-CDD8-4F92-83B7-4350D0840DDEQ35943499-8C60A684-70C3-42B4-9726-68386515079DQ35984696-1F782B41-402C-4B4C-BD12-64D2E7CFF54DQ36066049-06D8CEDA-1755-42A6-A548-7AC7DBC79611Q36161138-D8AD3EC7-60EB-4D84-B7FC-8B63E036A52BQ36200924-8E670D59-B773-42B5-A1A7-56F394F12E9FQ36242390-B393B5AE-14F6-4A14-A711-DCB4BBABB861Q36297613-44903785-D2E8-4175-BB87-F1E1690AB898Q36313966-DC413625-9D16-46A5-A776-6D4EF583ECA2Q36324841-064A813C-3BA4-48F6-B5E5-858F4E61A15FQ36407311-930FBB01-575D-4C3C-BA5C-7016759583F1Q36585191-54003D59-1247-4A42-8295-94F04D540784Q36808641-2EF5AD6D-9111-47D5-B26E-CD50978044B6Q38817006-121E9063-46A7-4908-A0C1-4071DBAB55C8Q38845769-3644048E-8D83-4EFB-9D60-E2CCBE557EA5Q38937864-44A9083B-FDD0-483B-AB6F-9805A53C3458Q39269575-69D5B45C-0AC6-407D-B312-CC0C39DD620CQ39427264-D9D76B49-2E6D-485A-A64F-F49801BF1503Q41025677-561877A4-5C35-41BE-9295-89B34DB3BFA8Q41363983-A3D9F5D0-892D-4ABB-AC93-97265ACFC4FCQ46249426-C120ADFD-3924-4D99-A4F7-BFA158143AB6Q47095285-78F638E0-643A-4A09-89E4-1AA1EFA684C4Q47166322-085357A3-34C2-47F2-9F36-984465A8C79BQ47168388-EA6F9A26-17F8-476B-BEB7-CE9078387903Q47310979-617F137B-38EA-4E05-ADA6-8AA1BDBD5A26Q47428173-4CE01E9B-7E01-45AD-A26C-98166823D35CQ48213638-C5FF5B43-892E-4095-BBF0-CE6C9B9D5936Q48357856-432C2C0D-A720-483D-81F0-6B41C4354898Q48579709-077D7FA8-8884-4A1A-A0DE-3DD935BB89F5Q49275652-AA0DA08F-284F-4A18-9AF1-27DF3011985EQ49882109-526CB222-E7B4-4C8B-BB27-146F2FA9DF85Q50095639-49359551-082E-42A4-BB4B-51AB91F6E51E
P2860
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@ast
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@en
type
label
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@ast
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@en
prefLabel
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@ast
Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.
@en
P2093
P1433
P1476
Intravitreal Aflibercept for D ...... om the VISTA and VIVID Studies
@en
P2093
Alyson J Berliner
Carola Metzig
Christian Simader
David M Brown
David S Boyer
Dennis M Marcus
Diana V Do
Edoardo Midena
Frank G Holz
George D Yancopoulos
P304
P356
10.1016/J.OPHTHA.2015.06.017
P577
2015-07-18T00:00:00Z